Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

By sjmartinez • December 9, 2022

Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Nov 13:S1558-7673(22)00238-5. doi: 10.1016/j.clgc.2022.11.003. Epub ahead of print. PMID: 36481176.

Tags: Badder cancer, Hematology/Oncology, immunotherapy, Publications, urinary tract cancer, urothelial cancer

Related Posts

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]

Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring

Lee J, Zhao C, Yang J, Jonas SJ, Agopian V, You S, Posadas E, Yang JD, Zhu Y, Tseng HR. Tumor Extracellular Vesicle Digital Scoring[...]